SI3999180T1 - Polimorfi(r)-n-(5-(5-etil-1,2,4-oksadiazol-3-il)-2,3-dihidro-1h-inden-1 -il)-1-metil-1h-pirazol-4-karboksamida - Google Patents

Polimorfi(r)-n-(5-(5-etil-1,2,4-oksadiazol-3-il)-2,3-dihidro-1h-inden-1 -il)-1-metil-1h-pirazol-4-karboksamida

Info

Publication number
SI3999180T1
SI3999180T1 SI202030443T SI202030443T SI3999180T1 SI 3999180 T1 SI3999180 T1 SI 3999180T1 SI 202030443 T SI202030443 T SI 202030443T SI 202030443 T SI202030443 T SI 202030443T SI 3999180 T1 SI3999180 T1 SI 3999180T1
Authority
SI
Slovenia
Prior art keywords
inden
oxadiazol
polymorphs
carboxamide
pyrazole
Prior art date
Application number
SI202030443T
Other languages
English (en)
Slovenian (sl)
Inventor
Norma TOM
Matthew Pfeiffer
Denise Andersen
Qi Gao
Original Assignee
Cytokinetics, Inc.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=71995103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3999180(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytokinetics, Inc., filed Critical Cytokinetics, Inc.,
Publication of SI3999180T1 publication Critical patent/SI3999180T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
SI202030443T 2019-07-17 2020-07-16 Polimorfi(r)-n-(5-(5-etil-1,2,4-oksadiazol-3-il)-2,3-dihidro-1h-inden-1 -il)-1-metil-1h-pirazol-4-karboksamida SI3999180T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962875350P 2019-07-17 2019-07-17
PCT/US2020/042387 WO2021011807A1 (en) 2019-07-17 2020-07-16 Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
EP20753562.6A EP3999180B1 (en) 2019-07-17 2020-07-16 Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide

Publications (1)

Publication Number Publication Date
SI3999180T1 true SI3999180T1 (sl) 2024-07-31

Family

ID=71995103

Family Applications (1)

Application Number Title Priority Date Filing Date
SI202030443T SI3999180T1 (sl) 2019-07-17 2020-07-16 Polimorfi(r)-n-(5-(5-etil-1,2,4-oksadiazol-3-il)-2,3-dihidro-1h-inden-1 -il)-1-metil-1h-pirazol-4-karboksamida

Country Status (25)

Country Link
US (1) US20220315571A1 (cg-RX-API-DMAC10.html)
EP (2) EP4487911A1 (cg-RX-API-DMAC10.html)
JP (2) JP7624431B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220084008A (cg-RX-API-DMAC10.html)
CN (3) CN118908951A (cg-RX-API-DMAC10.html)
AU (1) AU2020313965B2 (cg-RX-API-DMAC10.html)
BR (1) BR112022000494A2 (cg-RX-API-DMAC10.html)
CA (1) CA3144975A1 (cg-RX-API-DMAC10.html)
CL (1) CL2022000054A1 (cg-RX-API-DMAC10.html)
DK (1) DK3999180T3 (cg-RX-API-DMAC10.html)
ES (1) ES2980885T3 (cg-RX-API-DMAC10.html)
FI (1) FI3999180T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20240713T1 (cg-RX-API-DMAC10.html)
HU (1) HUE066891T2 (cg-RX-API-DMAC10.html)
IL (1) IL289875B1 (cg-RX-API-DMAC10.html)
LT (1) LT3999180T (cg-RX-API-DMAC10.html)
MX (1) MX2022000504A (cg-RX-API-DMAC10.html)
PH (1) PH12022550123A1 (cg-RX-API-DMAC10.html)
PL (1) PL3999180T3 (cg-RX-API-DMAC10.html)
PT (1) PT3999180T (cg-RX-API-DMAC10.html)
RS (1) RS65611B1 (cg-RX-API-DMAC10.html)
SI (1) SI3999180T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202400224T1 (cg-RX-API-DMAC10.html)
TW (1) TWI865562B (cg-RX-API-DMAC10.html)
WO (1) WO2021011807A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006296YA (en) 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
MX2022000498A (es) 2019-07-17 2022-02-03 Cytokinetics Inc Polimorfos de (r)-n-(5-(5-isopropil-1,2,4-oxadiazol-3-il)-2,3-dihi dro-1h-inden-1-il) -2-metil-2h- tetrazol-5-carboxamida.
KR20240015622A (ko) 2021-03-04 2024-02-05 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
EP4370116B1 (en) 2021-07-16 2025-01-15 Cytokinetics, Inc. Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy
JP2024530111A (ja) 2021-08-03 2024-08-16 サイトキネティックス, インコーポレイテッド アフィカムテンを調製するための工程
US20240091203A1 (en) 2022-07-20 2024-03-21 Cytokinetics, Incorporated Methods for treating non-obstructive hypertrophic cardiomyopathy
JP2025525913A (ja) 2022-08-04 2025-08-07 サイトキネティックス, インコーポレイテッド 閉塞性肥大型心筋症を治療するための方法
WO2024134498A1 (en) 2022-12-22 2024-06-27 Assia Chemical Industries Ltd. Solid state forms of aficamten and process for preparation thereof
CN120712262A (zh) * 2023-03-02 2025-09-26 苏州科睿思制药有限公司 Aficamten的共晶及其制备方法和用途
WO2025198687A1 (en) 2024-03-20 2025-09-25 Cytokinetics, Incorporated Methods for treating heart diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006296YA (en) * 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP2024530111A (ja) * 2021-08-03 2024-08-16 サイトキネティックス, インコーポレイテッド アフィカムテンを調製するための工程

Also Published As

Publication number Publication date
IL289875B1 (en) 2026-05-01
CA3144975A1 (en) 2021-01-21
NZ784930A (en) 2025-03-28
IL289875A (en) 2022-03-01
EP4487911A1 (en) 2025-01-08
EP3999180B1 (en) 2024-05-08
JP2022540668A (ja) 2022-09-16
KR20220084008A (ko) 2022-06-21
TWI865562B (zh) 2024-12-11
CN114555590A (zh) 2022-05-27
CN118908951A (zh) 2024-11-08
ES2980885T3 (es) 2024-10-03
JP2025061484A (ja) 2025-04-10
HRP20240713T1 (hr) 2024-09-13
EP3999180A1 (en) 2022-05-25
MX2022000504A (es) 2022-02-10
US20220315571A1 (en) 2022-10-06
CN114555590B (zh) 2024-09-10
BR112022000494A2 (pt) 2022-03-03
PH12022550123A1 (en) 2022-12-19
JP7755090B2 (ja) 2025-10-15
PT3999180T (pt) 2024-06-25
AU2020313965B2 (en) 2026-06-18
AU2020313965A1 (en) 2022-03-03
CL2022000054A1 (es) 2022-10-07
LT3999180T (lt) 2024-08-26
JP7624431B2 (ja) 2025-01-30
PL3999180T3 (pl) 2024-09-23
WO2021011807A1 (en) 2021-01-21
DK3999180T3 (da) 2024-05-21
RS65611B1 (sr) 2024-07-31
FI3999180T3 (fi) 2024-06-18
SMT202400224T1 (it) 2024-07-09
TW202116763A (zh) 2021-05-01
HUE066891T2 (hu) 2024-09-28
CN119119018A (zh) 2024-12-13

Similar Documents

Publication Publication Date Title
IL289875B1 (en) 3. Polymorphs of (R)-N-(5-(5-ETHYL-1,2,4-OXADIAZOL-3-YL)-2,3-DIHYDRO-1H-INDEN-1-YL)-1-METHYL-1H-PYRAZOLE-4-CARBOXAMIDE
IL289881A (en) Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h- tetrazole-5-carboxamide
PH12020551304A1 (en) Novel crystalline forms
PH12022550083A1 (en) Cardiac sarcomere inhibitor oral formulations
IL287030A (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide as raf inhibitors for cancer therapy
SI3464265T1 (sl) Polimorfi N-((3-fluoro-4-metoksipiridin-2-IL)metil)-3-(metoksimetil)- 1-((4-(2-oksopiridin-1-IL)metil)fenil)pirazol-4-karboksamida kot zaviralci kalikreina
IL285675A (en) Crystalline form of 1-(1-oxo-2,1-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate
MX2024001294A (es) Proceso para la preparacion de aficamten.
PL3464276T3 (pl) Nowa postać krystaliczna n-[5-(3,5-difluoro-benzylo)-1h-indazol-3-ilo)-4-(4-metylopiperazyn-1-ylo)-2-tetrahydropiran-4-yloamino)-benzamidu
ME03723B (me) 2-amin0-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridini kао васе1 inhibiтori
IL272992A (en) Solid structures of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-N-benzylacetamide
CA3307653A1 (en) An ethanesulfonate salt of the free base of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide
SI3298008T1 (sl) Kristalinična oblika spojine (S)-3-(4-(5-(2-ciklopentil-6-metoksi-piridin-4-IL)-(1,2,4)oksadiazol-3- IL)-2-etil-6-metil-fenoksi)-propan 1,2-diol
HK40075684B (en) Polymorphs of (r)-n-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-1-methyl-1h-pyrazole-4-carboxamide
IL254943A0 (en) -(4-(4-(((3r,5r)-5-((1h-4,2,1-triazol-1-yl)methyl)-5-(4,2-difluorophenyl)tetrahydrofuran-3-yl (Methoxy)-3-methylphenyl)piperazin-1-yl)-n-(2-hydroxycyclohexyl)benzamide antifungal or a pharmaceutically acceptable salt thereof
HK40074727A (en) Polymorphs of (r)-n-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1h-inden-1-yl)-2-methyl-2h-tetrazole-5-carboxamide
HK40065506A (en) Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate
UA111920C2 (uk) Амоній 2-(5-(феноксиметил)-1н-1,2,4-триазол-3-ілтіо)ацетат, що виявляє гіпоглікемічну активність
HK40025190A (en) Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide
UA97633U (xx) 3-((2-хлоретил)тіо)-5-(4-метоксифеніл)-1н-1,2,4-триазол, що проявляє гіпоглікемічну активність